Abiraterone acetate: a potential source of interference in testosterone assays.
Prostate cancer is the second most common cause of cancer in the UK with one in eight men diagnosed during their lifetime. Prostate cancer is typically dependent on androgens for growth, survival and metastasis. Androgen deprivation therapy targets this dependency through drugs such as luteinizing h...
Հիմնական հեղինակներ: | Fairfax, B, Morgan, R, Protheroe, A, Shine, B, James, T |
---|---|
Ձևաչափ: | Journal article |
Լեզու: | English |
Հրապարակվել է: |
De Gruyter
2018
|
Նմանատիպ նյութեր
-
The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels
: Gustavo Werutsky, և այլն
Հրապարակվել է: (2019-05-01) -
Abiraterone acetate in combination with prednisone in the treatment of metastatic hormone-sensitive prostate cancer: clinical evidence and experience
: Karin Purshouse, և այլն
Հրապարակվել է: (2019-01-01) -
SPECTROPHOTOMETRIC AND LUMINESCENCE DETERMINATION OF ABIRATERONE ACETATE
: I. I. Leonenko, և այլն
Հրապարակվել է: (2015-02-01) -
Abiraterone Acetate Withdrawal Syndrome: Does It Exist
: Hélène Gauthier, և այլն
Հրապարակվել է: (2012-07-01) -
Abiraterone Acetate and Castration Resistant Ductal Adenocarcinoma of the Prostate
: Edgar Linden-Castro, և այլն
Հրապարակվել է: (2014-01-01)